Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

S 32504

Known as: S-32504, S32504 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oxazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: improvements of affinity and selectivity for D3 versus D2 receptors.
Starting with the preferential dopamine (DA) D(3) agonist S32504, we prepared two series of derivatives of the general formula I… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
2006
2006
Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and…
RationaleDrug-discrimination studies have proven instructive in the characterization of psychotropic agents, a procedure applied… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
2006
2006
Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors
L‐dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D3/D2 receptor… Expand
Highly Cited
2004
Highly Cited
2004
S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: III. Actions in Models of Potential Antidepressive and Anxiolytic Activity in Comparison with Ropinirole
In forced-swim tests in mice and rats, the novel D3/D2 receptor agonist S32504 [(+)-trans-3,4,4a,5,6,10b-hexahydro-9-carbamoyl-4… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2004
2004
S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole
These studies evaluated the potential antiparkinsonian properties of the novel dopamine D3/D2 receptor agonist S32504 [(+)-trans… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • figure 5
2004
2004
Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells.
Anti-parkinsonian agents possessing both D(2) and D(3) receptor agonist properties are neuroprotective against 1-methyl-4… Expand
2004
2004
S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: I. Cellular, Electrophysiological, and Neurochemical Profile in Comparison with Ropinirole
S32504 [(+)-trans-3,4,4a,5,6,10b-hexahydro-9-carbamoyl-4-propyl-2H-naphth[1,2-b]-1,4-oxazine] displayed marked affinity for… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2003
Highly Cited
2003
Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole
Recombinant, human dopamine D3 and D2 receptors form functional heterodimers upon co‐expression in COS‐7 cells. Herein, actions… Expand
Highly Cited
2003
Highly Cited
2003
Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6…
The novel naphtoxazine derivative and preferential D(3) vs D(2) receptor agonist, S32504, restores perturbed motor function in… Expand
2003
2003
Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice
To test the modulatory role of D(3) receptors in normal and dopamine-depleted mice, D(3) receptor KO mice and wild-type (WT… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE